Colin G. Fishwick

Leeds, ENG LS29JT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Identification and characterization of candidate inhibitors of the SARS-CoV-2 nsp14 3'-5' exoribonuclease.

Identification and characterization of candidate inhibitors of the SARS-CoV-2 nsp14 3'-5' exoribonuclease.

Journal: The Journal of general virology

Published: December 19, 2025

Discovery of three small-molecule inhibitors targeting Ebolavirus genome replication and transcription.

Discovery of three small-molecule inhibitors targeting Ebolavirus genome replication and transcription.

Journal: The Journal of general virology

Published: December 01, 2025

Development of novel benzamide class I selective lysine deacetylase inhibitors as potent anticancer agents.

Development of novel benzamide class I selective lysine deacetylase inhibitors as potent anticancer agents.

Journal: Journal of enzyme inhibition and medicinal chemistry

Published: July 01, 2025

Identification of Ribonuclease Inhibitors for the Control of Pathogenic Bacteria.

Identification of Ribonuclease Inhibitors for the Control of Pathogenic Bacteria.

Journal: International journal of molecular sciences

Published: June 25, 2024

Using site-directed mutagenesis to further the understanding of insulin receptor-insulin like growth factor-1 receptor heterodimer structure.

Using site-directed mutagenesis to further the understanding of insulin receptor-insulin like growth factor-1 receptor heterodimer structure.

Journal: Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

Published: April 04, 2024

Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV.

Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: December 24, 2022

De novo design of type II topoisomerase inhibitors as potential antimicrobial agents targeting a novel binding region.

De novo design of type II topoisomerase inhibitors as potential antimicrobial agents targeting a novel binding region.

Journal: RSC medicinal chemistry

Published: February 16, 2022

From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor.

From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor.

Journal: Journal of medicinal chemistry

Published: November 15, 2021

From TgO/GABA-AT, GABA, and T-263 Mutant to Conception of Toxoplasma.

From TgO/GABA-AT, GABA, and T-263 Mutant to Conception of Toxoplasma.

Journal: iScience

Published: October 21, 2021

Recent developments in the structural characterisation of the IR and IGF1R: implications for the design of IR-IGF1R hybrid receptor modulators.

Recent developments in the structural characterisation of the IR and IGF1R: implications for the design of IR-IGF1R hybrid receptor modulators.

Journal: RSC medicinal chemistry

Published: September 08, 2021

Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C β-Lactamase from Escherichia coli.

Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C β-Lactamase from Escherichia coli.

Journal: Biomolecules

Published: April 30, 2020

Author Correction: New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections.

Author Correction: New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections.

Journal: Scientific reports

Published: April 07, 2020

Showing 1-12 of 65

Last Updated: 09/26/2026